[Physiopathology of cardiovascular disease in HIV-infected patients]

Area of Science:

• Cardiovascular Science
• Infectious Disease Immunology
• Molecular Biology

Context:

• Patients with Human Immunodeficiency Virus (HIV) exhibit a significantly higher risk of cardiovascular events, particularly those linked to arteriosclerosis.
• The HIV virus actively replicates within the arterial wall, triggering severe inflammatory responses and dysfunction.
• Metabolic disorders often associated with HIV infection and its treatments exacerbate this inflammatory state, accelerating atheroma plaque progression.

Purpose:

• To elucidate the intricate mechanisms by which HIV infection promotes accelerated atherosclerosis and cardiovascular events.
• To detail the molecular and cellular pathways involved in HIV-associated atheroma plaque development and complication.

Summary:

• HIV replicates in CD4+ T lymphocytes within the arterial wall, leading to the production of viral proteins like Tat.
• Tat induces chemokines (e.g., MCP-1) that attract monocytes, which become infected and promote endothelial dysfunction.
• Viral proteins, including Nef, disrupt cholesterol transport by blocking receptors (e.g., ABCA1), causing rapid plaque accumulation and complication.

Impact:

• Understanding these mechanisms is crucial for developing targeted therapies to mitigate cardiovascular risk in HIV patients.
• This research highlights the complex interplay between viral infection, inflammation, metabolic dysregulation, and atherogenesis.
• The findings provide a basis for novel preventative and therapeutic strategies against HIV-associated cardiovascular disease.